肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2008年
7期
452-453
,共2页
胡以则%陈德%陈德基%彭和平%林景泰%邓一文%薛平
鬍以則%陳德%陳德基%彭和平%林景泰%鄧一文%薛平
호이칙%진덕%진덕기%팽화평%림경태%산일문%설평
肝肿瘤%肝切除术%化学栓塞,治疗性%化学疗法,肿瘤,局部灌注
肝腫瘤%肝切除術%化學栓塞,治療性%化學療法,腫瘤,跼部灌註
간종류%간절제술%화학전새,치료성%화학요법,종류,국부관주
Liver neoplasms%Hepatectomy%Chemoembolization,therapeutic%Chemotherapy,cancer,regional perfusion%Hepatocellular
目的 探讨肝癌手术综合治疗及术后复发预防的合理方案.方法 回顾性总结手术治疗316例原发性肝癌,将肝切除的患者分为三组,进行术后无瘤生存率的比较.第一组为单一肝切除组(n=218),第二组为术前肝动脉化疗栓塞(TACE)+肝切除组(n=52),第三组为术前TACE+肝切除+术后门静脉化疗组,称为肝切除序贯双管疗法(n=46).结果 第一组术后1、3、5年生存率分别为51.2%、30.0%和20.5%,第二组分别为57.2%、43.0%、31.5%,第三组分别为84.0%、62.5%和51.0%.第三组患者与第一组和第二组患者的术后生存率差异均有统计学意义(P<0.05).结论 肝切除序贯双管疗法可以提高肝癌患者的生存率,在推迟和预防术后复发方面起到了积极作用.
目的 探討肝癌手術綜閤治療及術後複髮預防的閤理方案.方法 迴顧性總結手術治療316例原髮性肝癌,將肝切除的患者分為三組,進行術後無瘤生存率的比較.第一組為單一肝切除組(n=218),第二組為術前肝動脈化療栓塞(TACE)+肝切除組(n=52),第三組為術前TACE+肝切除+術後門靜脈化療組,稱為肝切除序貫雙管療法(n=46).結果 第一組術後1、3、5年生存率分彆為51.2%、30.0%和20.5%,第二組分彆為57.2%、43.0%、31.5%,第三組分彆為84.0%、62.5%和51.0%.第三組患者與第一組和第二組患者的術後生存率差異均有統計學意義(P<0.05).結論 肝切除序貫雙管療法可以提高肝癌患者的生存率,在推遲和預防術後複髮方麵起到瞭積極作用.
목적 탐토간암수술종합치료급술후복발예방적합리방안.방법 회고성총결수술치료316례원발성간암,장간절제적환자분위삼조,진행술후무류생존솔적비교.제일조위단일간절제조(n=218),제이조위술전간동맥화료전새(TACE)+간절제조(n=52),제삼조위술전TACE+간절제+술후문정맥화료조,칭위간절제서관쌍관요법(n=46).결과 제일조술후1、3、5년생존솔분별위51.2%、30.0%화20.5%,제이조분별위57.2%、43.0%、31.5%,제삼조분별위84.0%、62.5%화51.0%.제삼조환자여제일조화제이조환자적술후생존솔차이균유통계학의의(P<0.05).결론 간절제서관쌍관요법가이제고간암환자적생존솔,재추지화예방술후복발방면기도료적겁작용.
Objective To summarize the experience of adjuvant therapy for primary hepatocellular carcinoma. Methods 316 cases of operable hepatocellular carcinoma were divided into three groups. Only hepatectomy were performed in group one (21 8cases).Preopemtive adjuvant TACE were done in group two (52 cases). Preoperative adjuvant TACE and postoperative trans-portal vein chemotherapy were done in group three (46 cases), which was named hepatectomy sequencing two vessel therapy. Results 1, 3 and 5 year survival rote were 51.2 %, 30.0 % and 20.5 % respectively in group one, 57.2 %, 43.0 % and 31.5 % in group two, 84.0 %, 62.5 % and 51.0 % in group three. The postoperative disease-free survival rate in group three was significantly higher than that in group one and group two (P <0.05). Conclusion Hepatectomy sequencing two vessels therapy in perioperative period might improve the survival rate, which can prevent and delay the incidence of recurrence and may improve the effect of liver resection.